Bausch Health Enhances Liver Disease Solutions with DURECT Acquisition Bausch Health's recent acquisition of DURECT Corporation aims to bolster its liver disease treatment portfolio, focusing on innovative therapies.

Bausch Health Enhances Liver Disease Solutions with DURECT Acquisition #Canada #Larsucosterol #DURECT_Corporation #Laval #Bausch_Health

DURECT Corporation Announces Q2 2025 Financial Results and Bausch Health Acquisition Update DURECT Corporation reveals its second quarter 2025 financial performance while providing insights into its pending acquisition by Bausch Health, including a cash offer and milestone payments.

DURECT Corporation Announces Q2 2025 Financial Results and Bausch Health Acquisition Update #USA #Acquisition #Cupertino #DURECT_Corporation #Bausch_Health

Bausch Health's Strategic Acquisition of DURECT Corporation for Liver Disease Innovation Bausch Health strengthens its pipeline by acquiring DURECT Corporation, focusing on innovative treatments for liver diseases, especially alcoholic hepatitis.

Bausch Health's Strategic Acquisition of DURECT Corporation for Liver Disease Innovation #United_States #Liver_Disease #DURECT_Corporation #Laval #Bausch_Health

DURECT Corporation Achieves Key Milestones in Q1 2025 Financial Report and Business Updates DURECT Corporation shares its Q1 2025 financial results and insights on business strategies, focusing on larsucosterol's Phase 3 trial for alcohol-associated hepatitis.

DURECT Corporation Achieves Key Milestones in Q1 2025 Financial Report and Business Updates #USA #Cupertino #Larsucosterol #DURECT_Corporation #alcohol-associated_hepatitis

DURECT Corporation Reveals 2024 Financial Performance and Strategic Developments DURECT Corporation shares its financial results for the fourth quarter and full year 2024, highlighting advancements in larsucosterol development.

DURECT Corporation Reveals 2024 Financial Performance and Strategic Developments #United_States #Cupertino #Larsucosterol #AHFIRM_Trial #DURECT_Corporation

DURECT Corporation to Present Breakthrough Epigenetic Therapies at Major Healthcare Conference Discover DURECT Corporation's plans to present its innovative epigenetic therapies at the upcoming Oppenheimer 35th Annual Healthcare Conference. Learn more about the company's advancements.

DURECT Corporation to Present Breakthrough Epigenetic Therapies at Major Healthcare Conference #United_States #Cupertino #Healthcare_Conference #Larsucosterol #DURECT_Corporation